NICHOLAS GUAN: Open Payments
NPI 1558503334 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,374 in 96 payments from 10 companies in 2025. Trend: 2023 $4,623 · 2024 $3,620 · 2025 $4,374
Food & beverage: $4,250Education: $124
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 14 | $755 |
| Neurocrine BioSciences, Inc. | 17 | $713 |
| Teva Pharmaceuticals USA, Inc. | 14 | $619 |
| ABBVIE INC. | 15 | $558 |
| E.R. Squibb & Sons, L.L.C. | 10 | $500 |
| Alkermes, Inc. | 8 | $471 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $413 |
| Otsuka America Pharmaceutical, Inc. | 4 | $190 |
| Bausch Health US, LLC | 4 | $90 |
| Janssen Pharmaceuticals, Inc | 2 | $65 |
Products named: Auvelity, INGREZZA, VRAYLAR, COBENFY, UZEDY, CAPLYTA, LYBALVI, REXULTI.
Industry payments across NY — which companies pay providers there.
